158 related articles for article (PubMed ID: 16385881)
1. [New fixed once daily combination as nucleoside backbone. Basis for long-term therapy success].
MMW Fortschr Med; 2005 Apr; 147 Spec No 1():66-8. PubMed ID: 16385881
[No Abstract] [Full Text] [Related]
2. Lamivudine for the treatment of HIV.
Kumar PN; Patel P
Expert Opin Drug Metab Toxicol; 2010 Jan; 6(1):105-14. PubMed ID: 20001611
[TBL] [Abstract][Full Text] [Related]
3. [Nucleoside analogs inhibiting reverse transcriptase: use in adult patient with HIV infection].
Aguirrebengoa K; Mallolas J; Uriz J; Torres Tortosa M
Enferm Infecc Microbiol Clin; 1996 Oct; 14 Suppl 1():3-9. PubMed ID: 9053024
[No Abstract] [Full Text] [Related]
4. [Improved long-term success. New nucleoside for once daily combinations].
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():31-3. PubMed ID: 15373043
[No Abstract] [Full Text] [Related]
5. [Approval of a new nucleoside. Component of complete once daily regimen].
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():91. PubMed ID: 15373067
[No Abstract] [Full Text] [Related]
6. Abacavir and lamivudine combination.
Somboonwit C; Kurtyka D; Velez AP
Expert Opin Drug Metab Toxicol; 2009 Dec; 5(12):1599-606. PubMed ID: 19929448
[TBL] [Abstract][Full Text] [Related]
7. Abacavir and lamivudine for the treatment of human immunodeficiency virus.
Rizzardini G; Zucchi P
Expert Opin Pharmacother; 2011 Sep; 12(13):2129-38. PubMed ID: 21787242
[TBL] [Abstract][Full Text] [Related]
8. Abacavir plus lamivudine: a thymidine analogue-sparing NRTI backbone.
Moyle GJ
AIDS Read; 2003 Nov; 13(11):528, 533-5. PubMed ID: 14649622
[No Abstract] [Full Text] [Related]
9. A new HAART on the horizon says the proof is in the potency.
AIDS Alert; 1999 Apr; 14(4):37-9. PubMed ID: 11366218
[TBL] [Abstract][Full Text] [Related]
10. [Valuable combination partner. Great benefit for therapy naive patients].
MMW Fortschr Med; 2004 Apr; 146 Spec No 1():82-4. PubMed ID: 15373061
[No Abstract] [Full Text] [Related]
11. Emtricitabine: new preparation. An antiretroviral very similar to lamivudine.
Prescrire Int; 2005 Apr; 14(76):54-6. PubMed ID: 15875341
[TBL] [Abstract][Full Text] [Related]
12. Sweet's syndrome following abacavir therapy.
Del Giudice P; Vandenbos F; Perrin C; Bernard E; Marq L; Dellamonica P
J Am Acad Dermatol; 2004 Sep; 51(3):474-5. PubMed ID: 15337997
[No Abstract] [Full Text] [Related]
13. Special issue on health risks of perinatal exposure to nucleoside reverse transcriptase inhibitors.
Walker VE; Poirier MC
Environ Mol Mutagen; 2007; 48(3-4):159-65. PubMed ID: 17358025
[No Abstract] [Full Text] [Related]
14. [Reliability: nevirapine. Highly effective + favorable influence on lipid profile].
MMW Fortschr Med; 2005 Apr; 147 Spec No 1():42-3. PubMed ID: 16385872
[No Abstract] [Full Text] [Related]
15. Ototoxicity associated with use of nucleoside analog reverse transcriptase inhibitors: a report of 3 possible cases and review of the literature.
Simdon J; Watters D; Bartlett S; Connick E
Clin Infect Dis; 2001 Jun; 32(11):1623-7. PubMed ID: 11340535
[TBL] [Abstract][Full Text] [Related]
16. [Reliable effectiveness for years with good long-term tolerance: 10 years nevirapine--a summary].
MMW Fortschr Med; 2008 Apr; 150 Spec No 1():70. PubMed ID: 19024921
[No Abstract] [Full Text] [Related]
17. Abacavir/lamivudine fixed-dose combination antiretroviral therapy for the treatment of HIV.
Achenbach CJ; Scarsi KK; Murphy RL
Adv Ther; 2010 Jan; 27(1):1-16. PubMed ID: 20204580
[TBL] [Abstract][Full Text] [Related]
18. Preliminary report on 1592.
AIDS Clin Care; 1997 Sep; 9(9):71. PubMed ID: 11364756
[TBL] [Abstract][Full Text] [Related]
19. First-line antiretroviral therapy in resource-limited settings: time to reconsider?
Adlington R; Richens J; Shahmanesh M
J Infect Dis; 2009 May; 199(9):1407; author reply 1407-8. PubMed ID: 19358673
[No Abstract] [Full Text] [Related]
20. Two-once-daily fixed-dose NRTI combinations for HIV.
Med Lett Drugs Ther; 2005 Feb; 47(1203):19-20. PubMed ID: 15767973
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
